aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
aTyr Pharma (Nasdaq: ATYR) has appointed Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich, who currently serves as Chief Commercial Officer at Neurocrine Biosciences, brings over 30 years of pharmaceutical industry experience. He has previously held positions at AstraZeneca, Amgen, Peninsula Pharmaceuticals, and Avanir Pharmaceuticals, where he was involved in the sales and marketing of notable drugs including Prilosec®, Epogen®, Enbrel®, and Neudexta®.
aTyr is a clinical-stage biotechnology company focused on developing first-in-class medicines from its tRNA synthetase platform. Their lead candidate, efzofitimod, is being developed for the treatment of interstitial lung disease.
aTyr Pharma (Nasdaq: ATYR) ha nominato Eric Benevich nel suo Consiglio di Amministrazione, con effetto dal 10 dicembre 2024. Benevich, attualmente Chief Commercial Officer presso Neurocrine Biosciences, porta con sé oltre 30 anni di esperienza nell'industria farmaceutica. Ha ricoperto in precedenza ruoli presso AstraZeneca, Amgen, Peninsula Pharmaceuticals e Avanir Pharmaceuticals, dove è stato coinvolto nelle vendite e nel marketing di farmaci noti come Prilosec®, Epogen®, Enbrel® e Neudexta®.
aTyr è una società biotecnologica in fase clinica focalizzata sullo sviluppo di farmaci innovativi dalla sua piattaforma tRNA sintetasi. Il loro candidato principale, efzofitimod, è in fase di sviluppo per il trattamento delle malattie polmonari interstiziali.
aTyr Pharma (Nasdaq: ATYR) ha nombrado a Eric Benevich en su Junta Directiva, con efecto a partir del 10 de diciembre de 2024. Benevich, que actualmente ocupa el cargo de Director Comercial en Neurocrine Biosciences, aporta más de 30 años de experiencia en la industria farmacéutica. Ha ocupado anteriormente puestos en AstraZeneca, Amgen, Peninsula Pharmaceuticals y Avanir Pharmaceuticals, donde estuvo involucrado en la venta y el marketing de medicamentos destacados como Prilosec®, Epogen®, Enbrel® y Neudexta®.
aTyr es una empresa biotecnológica en fase clínica centrada en desarrollar medicamentos innovadores a partir de su plataforma de sintetasa de tRNA. Su candidato principal, efzofitimod, se está desarrollando para el tratamiento de enfermedades pulmonares intersticiales.
aTyr Pharma (Nasdaq: ATYR)는 Eric Benevich를 이사회에 임명하며, 2024년 12월 10일부터 발효됩니다. 현재 Neurocrine Biosciences의 최고 상업 책임자 역할을 수행하고 있는 Benevich는 30년 이상의 제약 산업 경험을 가지고 있습니다. 그는 이전에 AstraZeneca, Amgen, Peninsula Pharmaceuticals, Avanir Pharmaceuticals에서 근무하였으며, Prilosec®, Epogen®, Enbrel®, Neudexta®와 같은 주요 약물의 판매 및 마케팅에 참여했습니다.
aTyr는 tRNA 합성효소 플랫폼을 통해 최초의 혁신 의약품을 개발하는 임상 단계의 생명공학 회사입니다. 그들의 주요 후보 물질인 efzofitimod는 간질성 폐 질환 치료를 위해 개발되고 있습니다.
aTyr Pharma (Nasdaq : ATYR) a nommé Eric Benevich au sein de son Conseil d'Administration, avec effet au 10 décembre 2024. Benevich, qui occupe actuellement le poste de directeur commercial chez Neurocrine Biosciences, apporte plus de 30 ans d'expérience dans l'industrie pharmaceutique. Il a précédemment occupé des postes chez AstraZeneca, Amgen, Peninsula Pharmaceuticals et Avanir Pharmaceuticals, où il a été impliqué dans les ventes et le marketing de médicaments notables, tels que Prilosec®, Epogen®, Enbrel® et Neudexta®.
aTyr est une société de biotechnologie en phase clinique qui se concentre sur le développement de médicaments de première classe à partir de sa plateforme de synthétase tRNA. Leur candidat principal, efzofitimod, est en cours de développement pour le traitement des maladies pulmonaires interstitielles.
aTyr Pharma (Nasdaq: ATYR) hat Eric Benevich in seinen Vorstand berufen, wirksam ab dem 10. Dezember 2024. Benevich, der derzeit als Chief Commercial Officer bei Neurocrine Biosciences tätig ist, bringt über 30 Jahre Erfahrung in der Pharmaindustrie mit. Zuvor hatte er Positionen bei AstraZeneca, Amgen, Peninsula Pharmaceuticals und Avanir Pharmaceuticals inne, wo er an den Verkäufen und dem Marketing namhafter Medikamente wie Prilosec®, Epogen®, Enbrel® und Neudexta® beteiligt war.
aTyr ist ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von First-in-Class-Medikamenten auf Basis seiner tRNA-Synthetase-Plattform konzentriert. Ihr Hauptkandidat, efzofitimod, wird zur Behandlung von interstitiellen Lungenerkrankungen entwickelt.
- Addition of experienced commercial leader with 30+ years in pharmaceutical industry
- Strategic appointment strengthens commercialization capabilities
- Board member brings successful track record in product launches and marketing
- None.
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company’s Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine).
“We are excited to welcome Eric Benevich to the Board of Directors,” said Timothy P. Coughlin, Chairman of the Board of aTyr. “His extensive background bringing new products to market and the knowledge and expertise he has gained from both building and leading commercial activities at biopharmaceutical companies will be an invaluable resource as aTyr continues its evolution towards commercialization.”
Mr. Benevich has served as Chief Commercial Officer of Neurocrine since May 2015 and is responsible for all aspects of commercial development, marketing, and sales of the Neurocrine product portfolio. Mr. Benevich has over 30 years of commercial experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at AstraZeneca, Amgen, Peninsula Pharmaceuticals, and Avanir Pharmaceuticals in the sales and marketing of drugs such as Prilosec®, Epogen®, Enbrel®, and Neudexta®. Mr. Benevich has a BBA in International Business from Washington State University.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential benefits that Mr. Benevich’s appointment will have on aTyr’s evolution towards commercialization. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com
FAQ
When did Eric Benevich join aTyr Pharma's Board of Directors?
What is Eric Benevich's current role outside of aTyr Pharma?
What is aTyr Pharma's lead therapeutic candidate?
What major pharmaceutical companies has Eric Benevich previously worked for?
